Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas (NFitor)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01412892|
Recruitment Status : Completed
First Posted : August 9, 2011
Last Update Posted : November 14, 2014
Patients with the genetic disorder neurofibromatosis Type 1 (NF1) are at increased risk of developing tumors of the central and peripheral nervous system. These include plexiform neurofibromas. The conventional treatment of these internal plexiform neurofibromas is surgery. This surgery can be possible on a single and limited tumor. On the other hand these tumors are often surgically intractable due to their multiplicity and their infiltrating characteristics Increased activity of mammalian target of rapamycin(mTOR) protein is seen in neurofibromas. mTOR inhibitor rapamycin , or its derivatives such as everolimus may slow or stop tumor growth in patients with NF1.
Primary objectives To determine whether everolimus has an effect on the volume of surgically intractable and life-threatening internal plexiform neurofibromas in patients with neurofibromatosis 1.
Secondary objectives To determine whether everolimus has an effect on the number and the volume of cutaneous neurofibromas; to determine whether everolimus modify the signaling pathways in cutaneous neurofibromas.
- Adults with neurofibromatosis type 1 with at least one internal plexiform neurofibroma, life-threatening or causing significant morbidity through compression of organs. This or these internal plexiform neurofibroma(s) should be intractable by surgery.
An open-label, single arm, non-randomized, single stage phase IIa study. Baseline phase: Baseline evaluations will be performed within 2 weeks, and up to a maximum of 4 weeks for specific exams, before the first dose of study drug.
Treatment phase/duration of treatment: All patients will be treated with RAD001 10 mg p.o daily dose for one year except in case of unacceptable toxicity, death, or discontinuation from the study for any other reason.
Follow-up phase: All patients will have two follow-up visits scheduled at 18 and 24 months after the first dose of the study drug to follow for adverse events (AEs) and serious adverse events (SAEs) that may have occurred after discontinuation from the study and for internal plexiform neurofibromas assessment.
Radiological review: All Magnetic Resonance Imaging (MRIs) obtained at baseline, during the treatment period and the follow-up period will be reviewed by the Neuroradiologist of the study.
|Condition or disease||Intervention/treatment||Phase|
|Neurofibromatosis Type 1 Plexiform Neurofibroma Neurofibromatoses||Drug: RAD001: Everolimus||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||October 2013|
|Actual Study Completion Date :||October 2014|
Drug: RAD001: Everolimus
10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
- Radiographic response assessed by MRI analysis [ Time Frame: after 1 year of treatment ]
- Radiographic response assessed by MRI analysis [ Time Frame: At 2 years ]
- Overall survival [ Time Frame: At 2 years ]
- Pain [ Time Frame: At 2 years ]
- Deficiency [ Time Frame: At 2 years ]
- Quality of life [ Time Frame: At 2 years ]
- adverse events [ Time Frame: At 2 years ]
- laboratory evaluations [ Time Frame: At 2 years ]
- measurement of vital signs [ Time Frame: At 2 years ]
- performance of physical examinations [ Time Frame: At 2 years ]
- all concomitant medications and therapies [ Time Frame: At 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01412892
|Henri Mondor Hospital|
|Creteil, France, 94010|
|Principal Investigator:||Pierre Wolkenstein, MD, PhD||Assistance Publique - Hôpitaux de Paris|